We're taking a closer look at Moderna today, as the chatter surrounding the stock has increased notably in the last few weeks. Today, its shares moved -2.6% compared to -1.0% for the S&P 500. Increased investor interest and volatility surrounding the stock are not reason enough to buy in -- you should first perform your own due diligence. Here are some figures that can get you started:
-
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally.
-
Moderna has moved -27.0% over the last year compared to 22.0% for the S&P 500 -- a difference of -49.0%
-
MRNA has an average analyst rating of buy and is -45.72% away from its mean target price of $180.76 per share
-
Its trailing 12 month earnings per share (EPS) is $2.82
-
Moderna has a trailing 12 month Price to Earnings (P/E) ratio of 34.8 while the S&P 500 average is 15.97
-
Its forward earnings per share (EPS) is $-5.16 and its forward P/E ratio is -19.0
-
MRNA has a Price to Earnings Growth (PEG) ratio of 0.5, which shows the company is very undervalued compared to its earnings growth estimates.
-
The company has a Price to Book (P/B) ratio of 2.21 in contrast to the S&P 500's average ratio of 2.95
-
Moderna is part of the Health Care sector, which has an average P/E ratio of 24.45 and an average P/B of 4.16
-
Moderna has on average reported free cash flows of $4.15 Billion over the last four years, during which time they have grown by an an average of 0.0%
